W. L. Gore & Associates Inc. has completed enrollment for the pivotal phase of its ASSURED study. This IDE trial is evaluating the Flagstaff, Ariz.-based company's Cardioform ASD occluder for the interventional closure of atrial septal defects (ASDs) sized 8 to 35 millimeters. Gore also recently reported the publication of data from the REDUCE clinical trial that could lead up to the FDA granting approval for patent foramen ovale (PFO) indication for the Cardioform septal occluder. Read More
